sirolimus国内价格

Sirolimus is a new type of immunosuppressant developed by Wyeth Company of the United States. In September 1999, the drug was approved by the US FDA and officially launched on the market. It is mainly used to prevent and treat rejection of kidney, liver and other transplants. It is especially suitable for patients with renal dysfunction, tremor and hypertension. Different from tacrolimus, which is a structural homologue, although it acts on the same receptor, its mechanism of action is different. It mainly inhibits the body's immune function by affecting unique cell signaling pathways.

In 2002, sirolimus was approved for domestic marketing. From that time on, patients have been able to purchase the drugs they need at major hospitals and pharmacies in the country. So, what is the price of sirolimus in the country?

According to the official display of the China Medical Information Query Platform, the reference price of this drug is 143.00$~2739.00$. Normally, patients can buy a box of the small-sized medicines they need for about $500. At present, Lepamin has been included in the medical insurance catalog and belongs to the Class B drug of medical insurance. This also means that when patients purchase the drug in China, they can rely on medical insurance to reimburse part of the cost, thereby reducing their out-of-pocket expenses and reducing their own financial burden. Normally, the medical insurance reimbursement ratio is around 70% to 80%. However, it is affected by the medical insurance policies of various regions and other factors, so there will be certain differences in the final reimbursement ratio. Specific patients can consult the relevant departments.

While overdoses with sirolimus have been reported, experience with this drug is limited. Generally speaking, adverse effects from overdose are consistent with those seen at recommended doses. All cases of overdose should be treated with general supportive care. Based on the poor water solubility of sirolimus and its high binding rate to red blood cells, it can be expected that dialysis will not be able to effectively remove the drug. Acute oral lethal doses in mice and rats exceed 800 mg/kg.